Why the study?
Does Dipaxin provide safe and predictable anticoagulation in patients with thromboembolic diseases?
Does Dipaxin provide safe and predictable anticoagulation in patients with thromboembolic diseases?
Dipaxin is a potent, reversible anticoagulant that provides predictable response and low bleeding risk, making it suitable for long-term maintenance therapy.
Answers are grounded in this paper and cite their sources.
Supports predictable Dipaxin anticoagulation with low bleeding; hypothesis-generating case report requiring prospective trials.
In the course of development of new anticoagulants, an indandione derivative has been subjected to a clinical evaluation. The new agent is one of the most potent hypoprothrombinemic substance known but it is readily counteracted with vitamin K. The agent was administered to a large series of patients with thromboembolic diseases and control of anticoagulant therapy was observed to be simple, reproducible, with a good predictability of response as well as with absence of toxic phenomena and a low order of bleeding complications. It has been administered to 11 patients for ambulant anticoagulant care for periods up to 18 months with satisfactory results and it appears to be especially suitable for long-term maintenance therapy.
No takes yet. Share an insight, caveat, or question.
Field et al. (1955) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: